JP2018536621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536621A5 JP2018536621A5 JP2018511684A JP2018511684A JP2018536621A5 JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5 JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- xaa
- cancer
- macrocycle
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214142P | 2015-09-03 | 2015-09-03 | |
| US62/214,142 | 2015-09-03 | ||
| US201662310254P | 2016-03-18 | 2016-03-18 | |
| US62/310,254 | 2016-03-18 | ||
| US201662344651P | 2016-06-02 | 2016-06-02 | |
| US201662344791P | 2016-06-02 | 2016-06-02 | |
| US62/344,791 | 2016-06-02 | ||
| US62/344,651 | 2016-06-02 | ||
| PCT/US2016/050194 WO2017040990A1 (en) | 2015-09-03 | 2016-09-02 | Peptidomimetic macrocycles and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536621A JP2018536621A (ja) | 2018-12-13 |
| JP2018536621A5 true JP2018536621A5 (enExample) | 2019-10-17 |
| JP6971970B2 JP6971970B2 (ja) | 2021-11-24 |
Family
ID=58188595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511684A Expired - Fee Related JP6971970B2 (ja) | 2015-09-03 | 2016-09-02 | ペプチド模倣大環状分子およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170114098A1 (enExample) |
| EP (1) | EP3344275B8 (enExample) |
| JP (1) | JP6971970B2 (enExample) |
| KR (1) | KR20180043835A (enExample) |
| CN (1) | CN108348571B (enExample) |
| AU (1) | AU2016315878A1 (enExample) |
| BR (1) | BR112018003985A2 (enExample) |
| CA (1) | CA2996685A1 (enExample) |
| IL (1) | IL257706A (enExample) |
| MX (1) | MX2018002723A (enExample) |
| WO (1) | WO2017040990A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720306A2 (pt) | 2006-12-14 | 2014-02-04 | Aileron Therapeutics Inc | Sistemas de macrociclização da bis-sufidrila |
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| CA2678941C (en) | 2007-02-23 | 2018-11-27 | Aileron Therapeutics, Inc. | Triazole macrocycle systems |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| BRPI1006139A2 (pt) | 2009-01-14 | 2017-05-30 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| WO2011038049A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| KR20180058866A (ko) | 2010-08-13 | 2018-06-01 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| BR112014009418A2 (pt) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| CN112500466B (zh) | 2012-02-15 | 2022-05-03 | 艾瑞朗医疗公司 | 拟肽大环化合物 |
| MX2015005244A (es) | 2012-11-01 | 2015-07-14 | Aileron Therapeutics Inc | Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos. |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| AU2015320545C1 (en) | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| AU2015320549A1 (en) | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US20190240210A1 (en) * | 2016-10-17 | 2019-08-08 | Daiichi Sankyo Company, Limited | Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor |
| EP3532464A4 (en) | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER |
| WO2018106870A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| JP2020519595A (ja) * | 2017-05-11 | 2020-07-02 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| JP7780857B2 (ja) * | 2017-06-01 | 2025-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| EP3810145A4 (en) | 2018-06-21 | 2022-06-01 | Icahn School of Medicine at Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| US11091522B2 (en) * | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2020036852A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| WO2020112868A1 (en) * | 2018-11-30 | 2020-06-04 | Aileron Therapeutics, Inc. | Combination therapy of peptidomimetic macrocycles |
| US20220040166A1 (en) * | 2018-12-11 | 2022-02-10 | Kartos Therapeutics | Methods and Compositions of Treating an Ophthalmic Condition |
| CN109731104A (zh) * | 2018-12-29 | 2019-05-10 | 苏州明基医院有限公司 | 一种多肽-稀土材料递送系统及制备方法和应用 |
| CN114173878A (zh) * | 2019-03-15 | 2022-03-11 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| WO2020198734A1 (en) * | 2019-03-28 | 2020-10-01 | The Penn State Research Foundation | Methods, compositions relating to treatment of cancer |
| EP3965824B1 (en) | 2019-05-06 | 2025-01-08 | Icahn School of Medicine at Mount Sinai | Heterobifunctional compounds as degraders of hpk1 |
| WO2021202961A1 (en) * | 2020-04-02 | 2021-10-07 | United States As Represented By Dept Of Veterans Affairs | Methods of treating immunotherapy resistant metastatic melanoma |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| MX2022015793A (es) | 2020-06-24 | 2023-02-27 | Pmv Pharmaceuticals Inc | Terapia de combinacion para tratamiento de cancer. |
| CN111825621A (zh) * | 2020-07-22 | 2020-10-27 | 天津理工大学 | 一种奥拉帕尼与丙二酸的共晶及其制备方法 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN115137731B (zh) * | 2022-05-19 | 2023-11-21 | 上海交通大学医学院附属新华医院 | Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用 |
| WO2024083223A1 (zh) * | 2022-10-21 | 2024-04-25 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| GB202219576D0 (en) * | 2022-12-22 | 2023-02-08 | Univ Court Univ Of Glasgow | Polypeptides |
| WO2025085740A1 (en) * | 2023-10-20 | 2025-04-24 | Alkermes, Inc. | Compound for use in treating narcolepsy |
| WO2025096608A1 (en) * | 2023-10-31 | 2025-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Egfr covalent inhibition with macrocycles |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5364851A (en) | 1991-06-14 | 1994-11-15 | International Synthecon, Llc | Conformationally restricted biologically active peptides, methods for their production and uses thereof |
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| US5824483A (en) | 1994-05-18 | 1998-10-20 | Pence Inc. | Conformationally-restricted combinatiorial library composition and method |
| US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
| US6713280B1 (en) | 1999-04-07 | 2004-03-30 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7202332B2 (en) | 2004-05-27 | 2007-04-10 | New York University | Methods for preparing internally constrained peptides and peptidomimetics |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| US7932397B2 (en) | 2006-11-22 | 2011-04-26 | Massachusetts Institute Of Technology | Olefin metathesis catalysts and related methods |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| BRPI0906685A2 (pt) | 2008-01-25 | 2016-10-11 | Massachusetts Inst Technology | catalisadores para reações de metátese incluindo metátese de olefina enantiosseletiva, e métodos relacionados |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| AU2009316288B2 (en) * | 2008-11-24 | 2016-05-19 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with improved properties |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP2534140B1 (en) | 2010-02-08 | 2018-04-11 | Trustees of Boston College | Efficient methods for z- or cis-selective cross-metathesis |
| KR20180058866A (ko) * | 2010-08-13 | 2018-06-01 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| CN112500466B (zh) * | 2012-02-15 | 2022-05-03 | 艾瑞朗医疗公司 | 拟肽大环化合物 |
| US20150011728A1 (en) * | 2012-02-22 | 2015-01-08 | New York University | Reversibly crosslinked helical hydrogen bond surrogate macrocycles |
| EA201690785A1 (ru) * | 2013-12-05 | 2016-10-31 | Ф. Хоффманн-Ля Рош Аг | Новая комбинированная терапия острого миелоидного лейкоза (омл) |
| AU2015320549A1 (en) * | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| AU2015320545C1 (en) * | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| SG11201707750YA (en) * | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
-
2016
- 2016-09-02 EP EP16843105.4A patent/EP3344275B8/en active Active
- 2016-09-02 CN CN201680064031.0A patent/CN108348571B/zh not_active Expired - Fee Related
- 2016-09-02 US US15/256,130 patent/US20170114098A1/en not_active Abandoned
- 2016-09-02 BR BR112018003985A patent/BR112018003985A2/pt not_active Application Discontinuation
- 2016-09-02 KR KR1020187009277A patent/KR20180043835A/ko not_active Ceased
- 2016-09-02 MX MX2018002723A patent/MX2018002723A/es unknown
- 2016-09-02 AU AU2016315878A patent/AU2016315878A1/en not_active Abandoned
- 2016-09-02 CA CA2996685A patent/CA2996685A1/en active Pending
- 2016-09-02 WO PCT/US2016/050194 patent/WO2017040990A1/en not_active Ceased
- 2016-09-02 JP JP2018511684A patent/JP6971970B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-25 IL IL257706A patent/IL257706A/en unknown
-
2020
- 2020-05-22 US US16/881,564 patent/US20200369728A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6971970B2 (ja) | ペプチド模倣大環状分子およびその使用 | |
| JP2018536621A5 (enExample) | ||
| CN109414470A (zh) | 用于拟肽大环化合物的伴随诊断工具 | |
| JP2018516844A (ja) | ペプチド模倣大環状分子およびその使用 | |
| US11091522B2 (en) | Peptidomimetic macrocycles and uses thereof | |
| CN106999541A (zh) | 拟肽大环化合物及其用途 | |
| JP2020519595A (ja) | ペプチド模倣大環状分子およびその使用 | |
| CN114173878A (zh) | 拟肽大环化合物及其用途 | |
| WO2020112868A1 (en) | Combination therapy of peptidomimetic macrocycles | |
| HK40043424A (en) | Peptidomimetic macrocycles and uses thereof |